Neuland Laboratories Ltd
NSE:NEULANDLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neuland Laboratories Ltd
Interest Income Expense
Neuland Laboratories Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
Interest Income Expense
-₹190.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Interest Income Expense
-₹3.2B
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-17%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Interest Income Expense
-₹552.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
22%
|
CAGR 10-Years
12%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Interest Income Expense
₹8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Interest Income Expense
-₹324.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
31%
|
CAGR 10-Years
2%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Interest Income Expense
-₹2.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-1%
|
|
Neuland Laboratories Ltd
Glance View
Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.
See Also
What is Neuland Laboratories Ltd's Interest Income Expense?
Interest Income Expense
-190.9m
INR
Based on the financial report for Dec 31, 2025, Neuland Laboratories Ltd's Interest Income Expense amounts to -190.9m INR.
What is Neuland Laboratories Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
1%
Over the last year, the Interest Income Expense growth was -100%. The average annual Interest Income Expense growth rates for Neuland Laboratories Ltd have been -18% over the past three years , 1% over the past five years .